Elanco Animal Health Inc
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| ELANCO ANIMAL HEALTH INCORPORATED | ||
| (Registrant) | ||
| Date: | February 24, 2026 | /s/ Jeffrey N. Simmons |
|---|---|---|
| Jeffrey N. Simmons | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| /s/ Jeffrey N. Simmons | Date: | February 24, 2026 |
|---|---|---|
| Jeffrey N. Simmons | ||
| President and Chief Executive Officer (principal executive officer) and Director | ||
| /s/ Robert M. VanHimbergen | Date: | February 24, 2026 |
| Robert M. VanHimbergen | ||
| Executive Vice President, Chief Financial Officer (principal financial officer) | ||
| /s/ James M. Meer | Date: | February 24, 2026 |
| James M. Meer | ||
| Senior Vice President, Chief Accounting Officer (principal accounting officer) | ||
| /s/ Lawrence E. Kurzius | Date: | February 24, 2026 |
| Lawrence E. Kurzius | ||
| Chairman of the Board | ||
| /s/ Kapila Kapur Anand | Date: | February 24, 2026 |
| Kapila Kapur Anand | ||
| Director | ||
| /s/ Art A. Garcia | Date: | February 24, 2026 |
| Art A. Garcia | ||
| Director | ||
| /s/ Michael J. Harrington | Date: | February 24, 2026 |
| Michael J. Harrington | ||
| Director | ||
| /s/ Paul Herendeen | Date: | February 24, 2026 |
|---|---|---|
| Paul Herendeen | ||
| Director | ||
| /s/ R. David Hoover | Date: | February 24, 2026 |
| R. David Hoover | ||
| Director | ||
| /s/ Deborah T. Kochevar Ph.D., DVM | Date: | February 24, 2026 |
| Deborah T. Kochevar Ph.D., DVM | ||
| Director | ||
| /s/ Stacey Ma Ph.D. | Date: | February 24, 2026 |
| Stacey Ma Ph.D. | ||
| Director | ||
| /s/ Kirk McDonald | Date: | February 24, 2026 |
| Kirk McDonald | ||
| Director | ||
| /s/ Denise Scots-Knight Ph.D. | Date: | February 24, 2026 |
| Denise Scots-Knight Ph.D. | ||
| Director | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.